Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRVg versus Verorab intradermal simulated rabies post-exposure prophylaxis study in Thailand
2019-004008-36Phase 3
- Sponsor
- Sanofi
- Start
- Sep 2020
- Modality
- Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of rabies virus inactivated antigen, A, rabies immune globulin (human) and Equine Rabies Immunoglobulin in rabies (6 arms), sponsored by Sanofi. Primary endpoint: Primary immunogenicity endpoint.
02
Drugs
rabies virus inactivated antigen, Arabies immune globulin (human)Equine Rabies Immunoglobulin
03
Conditions
rabies
Beyond the preview
Go deeper on 2019-004008-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004008-36.